Shaping the future of healthcare

Dr. Jochen Schmitz, CFO | Dr. Michel Therin, Head of Advanced Therapies

August 8, 2019
Notes and forward looking statements

This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation is held or accessing this presentation, you agree to be bound by the following limitations.

This presentation has been prepared for information purposes only and the information contained herein (unless otherwise indicated) has been provided by Siemens Healthineers AG. It does not constitute or form part of, and should not be construed as, an offer of, a solicitation of an offer to buy, or an invitation to subscribe for, underwrite or otherwise acquire, any securities of Siemens Healthineers AG or any existing or future member of the Siemens Healthineers Group (the “Group”) or Siemens AG, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of Siemens Healthineers AG, any member of the Group or Siemens AG or with any other contract or commitment whatsoever. This presentation does not constitute a prospectus in whole or in part, and any decision to invest in securities should be made solely on the basis of the information to be contained in a prospectus and on an independent analysis of the information contained therein.

Any assumptions, views or opinions (including statements, projections, forecasts or other forward-looking statements) contained in this presentation represent the assumptions, views or opinions of Siemens Healthineers AG, unless otherwise indicated, as of the date indicated and are subject to change without notice. All information not separately sourced is from internal company data and estimates. Any data relating to past performance contained herein is no indication as to future performance. The information in this presentation is not intended to predict actual results, and no assurances are given with respect thereto.

The information contained in this presentation has not been independently verified, and no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information contained herein and no reliance should be placed on it. None of Siemens Healthineers AG or any of its affiliates, advisers, connected persons or any other person accept any liability for any loss howsoever arising (in negligence or otherwise), directly or indirectly, from this presentation or its contents or otherwise arising in connection with this presentation. This shall not, however, restrict or exclude or limit any duty or liability to a person under any applicable law or regulation of any jurisdiction which may not lawfully be disclaimed (including in relation to fraudulent misrepresentation).

This document contains statements related to our future business and financial performance and future events or developments involving Siemens Healthineers that may constitute forward-looking statements. These statements may be identified by words such as “expect”, “forecast”, “anticipate”, “intend”, “plan”, “believe”, “seek”, “estimate”, “will”, “target” or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. These statements are based on the current expectations and certain assumptions of Siemens Healthineers’ management, of which many are beyond Siemens Healthineers’ control. As they relate to future events or developments, these statements are subject to a number of risks, uncertainties and factors, including, but not limited to those described in the respective disclosures. Should one or more of these risks, uncertainties or factors materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Siemens Healthineers may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. All forward-looking statements refer to the date when they were made and Siemens Healthineers neither intends, nor assumes any obligation, unless required by law, to update or revise these forward-looking statements in light of developments which differ from those anticipated.

This document includes – in the applicable financial reporting framework not clearly defined – supplemental financial measures that are or may be alternative performance measures (non-GAAP measures). These supplemental financial measures may have limitations as analytical tools and should not be viewed in isolation or as alternatives to measures of Siemens Healthineers’ net assets and financial positions or results of operations as presented in accordance with the applicable financial reporting framework in its half-year consolidated financial statements and consolidated financial statements. Other companies that report or describe similarly titled alternative performance measures may calculate them differently, which may therefore not be comparable.

Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer.

The information contained in this presentation is provided as of the date of this presentation and is subject to change without notice.
Tapping into adjacent growth markets – We execute on our strategy

Strategic posture

Drive profitable growth in core business

Tap into adjacent growth markets

"Market leadership 2025"

Strategic priorities

• Significant next generation product and platform launches (e.g. Atellica)
• Structural cost savings

Mid-term and beyond

Reinforcing

Mid-term

Upgrading

New growth

2017-19

... move into

Digital, data and AI

Precision medicine

Patient journey stewardship

Therapy of tomorrow

Technology enabled services
Advanced Therapies is set to capture growth

Advanced Therapies at a glance FY2018

<table>
<thead>
<tr>
<th></th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>€1.5bn</td>
</tr>
<tr>
<td>Adjusted profit margin</td>
<td>19.6%</td>
</tr>
<tr>
<td>Recurring service revenue</td>
<td>~40%</td>
</tr>
</tbody>
</table>

Clinical fields

- Cardiology
- Interventional Radiology
- Radiation Oncology
- Surgery

Growth opportunities in complex cases

- Coronary CTO
  - Revascularization  +3%
- Peripheral Revascularization  +6%
- Catheter-based cancer treatment  +7%
- Endovascular stroke treatment  +20%

Leading position in image-guided therapies

Strong adoption of endovascular robotics (EVR) anticipated

---

1) Breakdown by geography based on location of customers  2) Based on equipment revenue  3) CAGR 13-24 on procedure growth, Source: Decision Resources Group Medtech 360 (Mar 2018) & own extrapolation  4) Chronic Total Occlusion
Corindus is forerunner in robotic-assisted vascular interventions

Corindus Vascular Robotics, Inc.

- Corindus is active in the development, manufacturing and selling of **robotic-assisted precision vascular systems, cassettes and services**
- **Headquartered** in Waltham, Massachusetts with ~100 employees
- Compelling **technology platform** for robotic-assisted coronary, peripheral, and neurovascular procedures

Key Investment Highlights

- **Superior technologies** that cover all major vascular segments promising significant radiation dose savings to operators and staff
- The first **FDA approved** and **CE marked** vascular robotics system
- **First mover advantage** with strong IP position
- Higher precision during catheter-based procedures will allow for **better outcomes, lower costs and higher quality of care**
- **Angiography systems** are essential for use of endovascular robotics, significant benefits from **tight integration** with Corindus portfolio

Continuous Innovation Pipeline

- **2012**
  - First system on market

- **2015**
  - FDA approval of CorPath for PCI

- **2016**
  - FDA approval of CorPath for PVI
  - FDA approval of CorPath GRX

- **2017**
  - First CorPath GRX installation outside US

- **2018**
  - FDA approval of CorPath GRX for PVI

- **2019**
  - CorPath GRX for Neuro pending 510(k)

**Siemens Healthineers will expedite innovation leadership in endovascular robotics**
Set to shape the market for robotic cardiovascular, peripheral and neurovascular procedures

**Procedural leadership**

- **Disruptive innovation pipeline** for cardiovascular, peripheral and neurovascular with **potential to shape endovascular robotics market**
- **Forerunner** in endovascular robotics with **significant first mover advantage**

**Our Vision**

- **Over 15% of complex interventions done with robotic support mid/long term**
- **Significant potential for robotic-assisted procedures**
- **Focus on vascular interventions, up to 20% growth p.a.**

**Combining strengths**

- Siemens Healthineers with Corindus will offer **unique, integrated solutions**
- **Leveraging** the Siemens Healthineers **installed base and customer service**, unlocking **synergy potential within sales, marketing and R&D**

Analyst Call, August 8
Unrestricted © Siemens Healthineers AG, 2019 | Page 6
Corindus is a valuable adjacency to our strong portfolio

Terms & Approvals

• Acquisition of 100% of fully diluted common shares outstanding of Corindus (NYSE: CVRS) for $4.28 per share:
  – Enterprise value of $1.1bn
  – 258 million\(^1\) fully diluted shares
  – 100% cash consideration
• Corindus board fully supports the acquisition proposal
• Transaction subject to Corindus’ shareholder and regulatory approvals

Financing, leverage & business profile post-closing

• Financed via new acquisition financing term loan by Siemens AG at arms-length
• Siemens Healthineers leverage well within solid investment grade rating
• Acquisition expected to deliver incremental, highly accretive topline growth
• Combination of high-growth market, R&D synergies and Siemens Healthineers’ scale has attractive bottomline potential

Timeline

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expected closing</td>
<td>Oct-Dec 2019</td>
</tr>
<tr>
<td>Q4 results with strategic &amp; financial update</td>
<td>Nov 2019</td>
</tr>
<tr>
<td>Meet-the-Management</td>
<td>Dec 2019</td>
</tr>
<tr>
<td>Corindus Integration</td>
<td>2020</td>
</tr>
</tbody>
</table>

1) As of signing